



Univ. Prof. Dr. Dr. med. Diamant Thaçi

Institute for Inflammation Medicine
 Center of Excellence for Inflammation Medicine
 Clinic for Dermatology, Allergology, and Venereology
 University Medical Center Schleswig-Holstein, Lübeck
 Campus University of Lübeck
 Ratzeburger Allee 160
 23538 Lübeck, Germany
 Tel. +49-451- 500- 41600
 Email: diamant.thaci@uksh.de

PROFESSIONAL CAREER

Postdoctoral Fellowship	1991
DAAD Scholarship for Highly Talented Young Scientists	1992-1994
Specialist Examination for Dermatology and Venereology, State Medical Association of Hesse	October 1995
Scientific Employee in the Immunology Laboratory ZDV, J.W. Goethe University, Frankfurt am Main	1995-1997
Clinical Research Lead in the Immunology Laboratory ZDV, J.W. Goethe University, Frankfurt am Main	1998-2001
Senior Physician, Department of Dermatology, Venereology, and Allergology, University Hospital of Goethe University Frankfurt	2001-2012
<ul style="list-style-type: none"> - Senior Physician Leader of Dermatological Clinical Research - Senior Physician Leader of Phototherapy and Photodynamic Therapy (PDT) - Senior Physician Leader of the Outpatient Clinic for Chronic Inflammatory Skin Diseases - Deputy Senior Physician for the University Outpatient Clinic 	
Venia legendi and private lecturer, J.W. Goethe University Frankfurt	2011-2012
W2 Professorship in Inflammation Medicine, Lübeck	2013-2017

CURRENT POSITION AND RESEARCH ENGAGEMENT

Head of the Inflammation Board UKSH Campus Lübeck, Germany	Since 2013
Head of the Excellence Center for Inflammation Medicine, University of Lübeck	Since 2013
Director of the Institute for Inflammation Medicine	Since 2016
Head of the Section of Inflammation Medicine, Department of Dermatology	Since 2017
Appointment to W3 Professorship for Inflammation Medicine with Lifetime Tenure	Since 2018

MEMBERSHIPS

- Member of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
- Active Member of the International Psoriasis Council (IPC)
- Active Member of the International Eczema Council (IEC)
- Member of ECCO (European Crohn's and Colitis Organisation) extra-intestinal diseases
- Active Member of Skin Inflammation & Psoriasis International Network (SPIN)
- Reviewer in the German Federal Ministry of Education and Research (BMBF) and Hessian Agency for Funding Projects
- Editor, Associated Editor und member of the Editorial Board for multiple scientific journals

TOP PUBLICATIONS FROM THE LAST 5 YEARS

1) Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. Bieber T, Simpson EL, Silverberg JI, **Thaçi D**, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. **N Engl J Med.** 2021 Mar 25;384(12):1101-1112.

2) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, **Thaçi D**, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. **Lancet.** 2021 Jun 5;397(10290):2151-2168.

3) Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor- α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, **Thaçi D**, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC. **Lancet.** 2023 Jan 7;401(10370):38-48.

4) Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, **Thaçi D**, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. **Lancet.** 2023 Oct 28;402(10412):1541-1551.

5) Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Silverberg JI, Wollenberg A, Reich A, **Thaçi D**, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE, Carrascosa JM, Rewerska B, Szepletowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S, Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C; ARCADIA 1 and ARCADIA 2 Study Investigators. **Lancet.** 2024 Aug 3;404(10451):445-460.

HONORS AND AWARDS

- Awarded the Theodor Stern Foundation Prize in 2005 for patient-oriented clinical research
- Highly Cited Researcher Award (Web of Science, Clarivate, 2021, 2024) with significant and broad influence in his field of research
- Principal Investigator in numerous national and international multicenter trials
- Over 600 scientific publications, h-Index=60, IF>1000, citations>20,000
- Multiple EADV awards for best presentations
- Several poster awards at congresses (EADV, ISD, DDG, AAD)
- Honorary Member of the Polish Dermatological Society
- Honorary Member of the Romanian Dermatological Society